InflaRx N.V. Showcases Promising Vilobelimab Data for Pyoderma Gangrenosum and Hidradenitis Suppurativa at AAD 2025 Annual Meeting

InflaRx presented vilobelimab data for pyoderma gangrenosum and hidradenitis suppurativa at AAD 2025, highlighting efficacy and safety.

Quiver AI Summary

InflaRx N.V. has announced the presentation of data on vilobelimab, its anti-inflammatory therapeutic targeting the complement system, at the 2025 American Academy of Dermatology Annual Meeting. The data covers its efficacy and safety in treating pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS). Chief Medical Officer Camilla Chong highlighted vilobelimab's potential benefits, including well-tolerated safety profiles and significant reductions in inflammatory mediators such as C5a. In the PG studies, vilobelimab showed no serious side effects and a notable decrease in C5a levels. For HS, the therapy demonstrated a significant reduction in draining tunnels and a higher rate of complete resolution compared to placebo. Overall, the data strengthens the case for vilobelimab's effectiveness in treating these inflammatory conditions.

Potential Positives

• InflaRx presented significant clinical efficacy data for vilobelimab in treating pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) at a prestigious medical conference, showcasing its potential in addressing serious inflammatory conditions.
• The data highlighted vilobelimab's favorable safety profile, indicating it was well-tolerated with no clinically relevant adverse effects, thus enhancing its viability as a treatment option.
• In HS, vilobelimab demonstrated a 3.1x relative improvement in complete resolution of draining tunnels (dT100) compared to placebo, indicating its effectiveness in treating this burdening symptom.

Potential Negatives

• Emergency Use Authorization for GOHIBIC (vilobelimab) in the U.S. is limited and is only valid during the COVID-19 pandemic, indicating uncertainty about the drug's long-term viability for this indication.
• No FDA approval exists for vilobelimab for any indication, including COVID-19, meaning the company is still in the investigational phase and market confidence may be affected.
• Data presented for vilobelimab in pyoderma gangrenosum suggests that higher doses are needed to be effective, which may complicate treatment regimens and patient compliance.

FAQ

What is vilobelimab and its primary use?

Vilobelimab is an investigational anti-C5a monoclonal antibody targeted at treating inflammatory diseases like pyoderma gangrenosum and hidradenitis suppurativa.

Where was vilobelimab presented recently?

Vilobelimab was presented at the 2025 American Academy of Dermatology Annual Meeting in Orlando, FL, showcasing its clinical efficacy and safety data.

What did the data reveal about vilobelimab's safety?

The data indicated that vilobelimab was well-tolerated, with most adverse events being mild to moderate, showing no specific safety concerns.

How effective is vilobelimab in reducing draining tunnels in HS?

Vilobelimab showed a 63.2% reduction in draining tunnel counts in hidradenitis suppurativa patients, significantly outperforming the placebo group.

What ongoing studies are related to vilobelimab?

An ongoing Phase 3 trial is assessing vilobelimab at a dose of 2400 mg bi-weekly for its efficacy in ulcerative pyoderma gangrenosum patients.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$IFRX Hedge Fund Activity

We have seen 15 institutional investors add shares of $IFRX stock to their portfolio, and 19 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• MORGAN STANLEY added 1,370,035 shares (+205.1%) to their portfolio in Q4 2024, for an estimated $3,383,986
• EVERSEPT PARTNERS, LP removed 1,129,335 shares (-69.6%) from their portfolio in Q4 2024, for an estimated $2,789,457
• IKARIAN CAPITAL, LLC removed 704,987 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,741,317
• NORTHERN TRUST CORP added 634,045 shares (+1933.1%) to their portfolio in Q4 2024, for an estimated $1,566,091
• WOODLINE PARTNERS LP removed 173,586 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $265,586
• OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) removed 172,287 shares (-21.6%) from their portfolio in Q4 2024, for an estimated $425,548
• UBS GROUP AG added 67,441 shares (+inf%) to their portfolio in Q4 2024, for an estimated $166,579

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), including clinical efficacy data, safety assessments, and pharmacokinetic (PK) and pharmacodynamic (PD) analyses. These data are being presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting being held March 7 - 11, in Orlando, FL.

Camilla Chong, MD, Chief Medical Officer of InflaRx

, commented: “At AAD 2025, we presented multiple data sets we believe collectively paint a broad and positive picture of vilobelimab’s potential in addressing inflammatory conditions such as hidradenitis suppurativa and pyoderma gangrenosum. Multiple safety analyses showed vilobelimab to be well-tolerated in HS, and in the rare and devastating disease of PG, in which patients are often very ill and have co-morbidities. We also presented data showing vilobelimab can reduce and resolve draining tunnels, including a 3.1x relative improvement in dT100 response. Multiple analyses also showed vilobelimab can promote significant and sustained reductions in C5a, which is a key mediator of the inflammatory cascade. We believe that the C5a/C5aR pathway remains critical in these neutrophilic-driven diseases.”

Vilobelimab in PG at AAD 2025



In PG, InflaRx presented two analyses from the previously completed Phase 2a dose-finding study. In an oral poster session (#63560), the Company presented safety data, showing that adverse events (AEs) were mostly mild to moderate. The data also showed vilobelimab to be well tolerated across all doses, with no specific safety concerns associated with vilobelimab and no dose relationship observed. In addition, no clinically relevant findings for vital signs, ECGs, hematology, clinical chemistries or urinalysis were seen.

In an ePoster (#63550), InflaRx presented PK/PD data in PG measuring relative changes in C5a concentrations from baseline in three vilobelimab dose groups. C5a decreased from baseline throughout the study, with an approximate 90% reduction observed by Day 15 in all dose groups and sustained in Group 2 (1600 mg bi-weekly) and Group 3 (2400 mg bi-weekly) out to Day 99. The PK/PD analysis also suggested that doses greater than 1600mg given bi-weekly of vilobelimab are needed in ulcerative PG patients to suppress C5a. The ongoing Phase 3 trial is utilizing vilobelimab dosed at 2400 mg bi-weekly.

Vilobelimab in HS at AAD 2025



InflaRx also presented multiple posters related to the Phase 2b SHINE trial studying vilobelimab in HS. A post-hoc analysis (#63490) assessed the impact of vilobelimab on reducing dT, which are a tremendous burden on patients and sometimes require invasive surgery. Vilobelimab showed a significantly greater reduction in mean dT count versus placebo of -63.2% versus -18.0%. Vilobelimab demonstrated a significantly higher rate of complete resolution of dT (dT100) versus placebo of 40.9% versus 13.0%, for a 3.1x relative responder improvement in favor of vilobelimab.

Additional data presented from SHINE included a safety analysis (#63527), which showed that vilobelimab was well tolerated with a similar frequency, severity and pattern of AEs observed at all doses compared to placebo. In addition, the extension trial period had similar rates and severity of AEs to the main trial period.

Featured in an ePoster (#63454), a PK/PD analysis showed that the administration of 800mg vilobelimab resulted in trough levels which significantly reduced C5a concentrations from Day 1. While C5a concentrations gradually increased after the treatment period, they remained lower than baseline during the follow-up to Day 134, indicating a residual treatment effect.

#63560




Oral poster presentation:


Vilobelimab Safety in Pyoderma Gangrenosum Patients: A Phase 2a Explorative Dose-Finding Study




Authors:

Afsaneh Alavi, Benjamin H. Kaffenberger, Hoda Tawfik, Camilla Chong, Bruce P. Burnett



Date/time:

Mar 8, 2025, 10:15 AM - 10:20 AM

#63550




ePoster

:

Pharmacokinetic/Pharmacodynamic Analysis of Vilobelimab and Complement C3 and C5a in a Randomized, Controlled Multidose Phase 2a Study in Pyoderma Gangrenosum




Authors:

Afsaneh Alavi, Hoda Tawfik, Camilla Chong, Joseph F. Grippo, Bruce P. Burnett

#63490




ePoster:


Reduction in Draining Tunnels in Hidradenitis Suppurativa Patients Treated with Vilobelimab in a Randomized, Placebo-Controlled, Double-Blind Multicenter Phase 2b Study




Authors:

Evangelos J. Giamarellos-Bourboulis, Christopher Sayed, Jamie Weisman, Jacek C Szepietowski, Falk Bechara, Hoda Tawfik, Camilla Chong, Bruce P. Burnett

#63505




ePoster:


Vilobelimab Post-hoc Efficacy in Hidradenitis Suppurativa using the Modified-HiSCR with Data from the Phase 2b SHINE Study




Authors:

Evangelos J. Giamarellos-Bourboulis, Christopher Sayed, Camilla Chong, Hoda Tawfik, Bruce P. Burnett

#63527




ePoster:


Vilobelimab Safety in Hidradenitis Suppurativa Patients in a Randomized, Placebo-Controlled, Double-Blind Multicenter Phase 2b study




Authors:

Evangelos J. Giamarellos-Bourboulis, Christopher Sayed, Jamie Weisman, Jacek C Szepietowski, Falk Bechara, Hoda Tawfik, Camilla Chong, Bruce P. Burnett

#63454




ePoster:


Pharmacokinetic/Pharmacodynamic Analysis of Vilobelimab Demonstrates a Significant Reduction of C5a Levels in Hidradenitis Suppurativa Patients




Authors:

Evangelos J. Giamarellos-Bourboulis, Theodora Kanni, Hoda Tawfik, Camilla Chong, Joseph F. Grippo, Bruce P. Burnett

About GOHIBIC (vilobelimab)



In the U.S., GOHIBIC (vilobelimab) has been granted an Emergency Use Authorization by the Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). The emergency use of GOHIBIC is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization revoked sooner.

GOHIBIC (vilobelimab) is an investigational drug that has not been approved by the FDA for any indication, including for the treatment of COVID-19. There is limited information known about the safety and effectiveness of using GOHIBIC to treat people in the hospital with COVID-19. Please see additional information in the Fact Sheet for Healthcare Providers, Fact Sheet for Patients and Parents/Caregivers and FDA Letter of Authorization on the GOHIBIC website

http://www.gohibic.com

.

In the EU, GOHIBIC (vilobelimab) has been granted marketing authorization under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (IMV) (with or without extracorporeal membrane oxygenation (ECMO)). The EU approval of GOHIBIC is supported by the previously announced results of the multicenter Phase 3 PANAMO trial, one of the largest 1:1 randomized, double-blind, placebo-controlled trials in invasively mechanically ventilated COVID-19 patients in intensive care units. The results showed that vilobelimab treatment improved survival with a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in the global data set. The data were published in The Lancet Respiratory Medicine.

A marketing authorization under exceptional circumstances is recommended when the benefit/risk assessment is determined to be positive but, due to the rarity of the disease, it’s unlikely that comprehensive data can be obtained under normal conditions of use. Under the terms of GOHIBIC’s approval in the EC, InflaRx will provide annual updates to EMA on the previously announced clinical platform study planned by the Biomedical Advanced Research and Development Authority (BARDA). Vilobelimab is included in this study as one of three new potential therapies for treating ARDS.

The COVID-19 related work described herein was partly funded by the German Federal Government through grant number 16LW0113 (VILO-COVID). All responsibility for the content of this work lies with InflaRx.

About InflaRx N.V.

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit

www.inflarx.com

.

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

FORWARD-LOOKING STATEMENTS



This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.